Official Title
Étude Des réponses Immunitaires Lymphocytaires spécifiques Chez Des Patients infectés Par le Virus SARS-CoV-2 : Caractéristiques Des Réponses Effectrices et Mémoires
Brief Summary

SARS-CoV-2, has caused an international outbreak of respiratory illness termed Covid-19. The investigators used peptides derived from SARS-CoV-2 virus, to study viral-specific immune responses. COV-CREM is a French prospective monocentric study that will evaluate viral-specific cell responses in positive patients for SARS-CoV-2 on the basis of (RT-PCR) assay performed in respiratory tract sample tested by our local Center for Disease Control.

SARS-CoV-2 Infection

Other: Additional biological samples

Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
Other Name: Additional blood samples will be realized as part of the care

Eligibility Criteria

Inclusion Criteria:

- COVID-19 PCR positive,

- Hospitalized patients with illness of any duration, and/or SpO2 ≤ 92% on room air.

- Cohorte C : patients with cancer (hematological malignancies and solid tumors).

Exclusion Criteria:

- Refusal to participate,

- Any immunosuppressive therapy (i.e. corticosteroids >10mg of hydrocortisone or
equivalent dose) within 14 days before the planned start of study,

- Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients),
or a known history of active Tuberculosis bacillus,

- Active autoimmune disease that required a systemic treatment, with the following

- Patients with a history of autoimmune-related hypothyroidism who are on thyroid
replacement hormone are eligible for the study,

- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen
are eligible for the study,

- Prior allogeneic bone marrow transplantation or prior solid organ transplantation,

- Patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-PD-1,
anti-PD-L1, or anti-CTLA4 agent or any immune therapy or biotherapy (except for
patients in cohort C),

- Previous prescribing of biotherapy or treatment for the management of COVID-19 is not
an exclusion criterion,

- Patient under guardianship, curatorship or under the protection of justice.

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A

CHU Jean Minjoz
Besançon, France

Investigator: Marie KROEMER, PharmD PhD


Marie KROEMER, PharmD PhD


Centre Hospitalier Universitaire de Besancon
NCT Number
MeSH Terms